MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1358/dot.2012.48.9.1835160

Медицинская библиотека · Drugs of today (Barcelona, Spain : 1998) · 2012

Lucinactant for the treatment of respiratory distress syndrome in neonates.

Piehl E, Fernandez-Bustamante A

СтатьяОбзорПеревод в очереди

Аннотация

Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality in premature neonates. This syndrome is caused by a lack of endogenous surfactant production in the lungs. Surfactant replacement was established as a safe and effective treatment in the 1990s and has become the standard of care for these infants. Surfactant products are either protein-free synthetic phospholipid compounds or animal-derived lung preparations. Currently, about 90,000 infants a year receive treatment with one of the commercially available animal-derived surfactants. Lucinactant (Surfaxin®) is a new synthetic surfactant with a pulmonary surfactant-associated protein B mimic that recently received FDA approval. The clinical trials that have been performed, although underpowered, may indicate that lucinactant is superior to phospholipid synthetic surfactant preparations and at least as effective as animal-derived surfactants in reducing morbidity and mortality from RDS. This review summarizes the current clinical knowledge about lucinactant.

Для цитирования: Piehl E, Fernandez-Bustamante A. Lucinactant for the treatment of respiratory distress syndrome in neonates.. Drugs of today (Barcelona, Spain : 1998). 2012. DOI: 10.1358/dot.2012.48.9.1835160.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.